A 12-Month, Prospective, Multicenter, Two-cohort, Nonrandomized, Open-label Study in Adult Patients With Relapsing Multiple Sclerosis (RMS), to Investigate Changes in Immune Phenotype Biomarkers After Treatment With 0.5mg Fingolimod [FLUENT]
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Pharmacodynamics
- Acronyms FLUENT
- Sponsors Novartis Pharmaceuticals
- 01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology
- 21 Aug 2019 Status changed from active, no longer recruiting to completed.
- 05 Jun 2019 Planned End Date changed from 30 Jul 2019 to 28 Jun 2019.